DK2637664T3 - Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension - Google Patents
Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension Download PDFInfo
- Publication number
- DK2637664T3 DK2637664T3 DK11833507.4T DK11833507T DK2637664T3 DK 2637664 T3 DK2637664 T3 DK 2637664T3 DK 11833507 T DK11833507 T DK 11833507T DK 2637664 T3 DK2637664 T3 DK 2637664T3
- Authority
- DK
- Denmark
- Prior art keywords
- ambrisentan
- tadalafil
- salt
- composition
- pah
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (11)
- SAMMENSÆTNINGER OG FREMGANGSMÅDER TIL BEHANDLING AF PULMONAL HYPERTENSION1. Sammensætning til anvendelse til behandling af pulmonal arteriel hypertension (PAH) hos en menneskelig patient ved tilpasning af et eller flere hæmodynamiske parametre til et mere normalt niveau versus baseline, hvilken sammensætning omfatter: en terapeutisk effektiv mængde af ambrisentan eller et salt deraf i kombination med en terapeutisk effektiv mængde af tadalafil eller et salt deraf, hvor vægtforholdet mellem ambrisentan eller saltet deraf og tadalafil eller saltet deraf ligger i området fra 1:1 til 1:10, og hvori virkningen af administration af den terapeutisk effektive mængde af ambrisentan eller saltet deraf i kombination med den terapeutisk effektive mængde af tadalafil eller saltet deraf er større end summen af virkningen af mono-administration af hvert middel.
- 2. Sammensætning til anvendelse ifølge krav 1, hvori vægtforholdet mellem ambrisentan eller saltet deraf og tadalafil eller saltet deraf ligger i området fra 1:2 til 1:5.
- 3. Sammensætning til anvendelse ifølge krav 1 eller 2, hvori sammensætningen administreres oralt eller parenteralt.
- 4. Sammensætning til anvendelse ifølge krav 1 eller 2, hvori sammensætningen er en tablet eller en kapsel.
- 5. Sammensætning til anvendelse ifølge krav 1 eller 2, hvori den terapeutisk effektive mængde af ambrisentan eller saltet deraf er fra 1 mg til 100 mg dagligt.
- 6. Sammensætning til anvendelse ifølge krav 5, hvori den terapeutisk effektive mængde af ambrisentan eller saltet deraf er fra 2 mg til 20 mg dagligt.
- 7. Sammensætning til anvendelse ifølge krav 1 eller 2, hvori den terapeutisk effektive mængde af tadalafil eller saltet deraf er fra 5 mg til 500 mg dagligt.
- 8. Sammensætning til anvendelse ifølge krav 7, hvori den terapeutisk effektive mængde af tadalafil eller saltet deraf er fra 10 mg til 100 mg dagligt.
- 9. Sammensætning til anvendelse ifølge krav 1 eller 2, hvori sammensætningen administreres én gang dagligt.
- 10. Sammensætning til anvendelse ifølge krav 1 eller 2, hvori PAH er idiopatisk PAH, familiær PAH eller PAH, der er forbundet med en anden sygdom eller tilstand.
- 11. Sammensætning til anvendelse ifølge krav 1 eller 2, hvori PAH ved baseline er af WHO-funktionsklasse II, III eller IV.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39352910P | 2010-10-15 | 2010-10-15 | |
| US201161490454P | 2011-05-26 | 2011-05-26 | |
| US201161497475P | 2011-06-15 | 2011-06-15 | |
| PCT/US2011/056404 WO2012051559A2 (en) | 2010-10-15 | 2011-10-14 | Compositions and methods of treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2637664T3 true DK2637664T3 (da) | 2017-06-19 |
Family
ID=45939010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11833507.4T DK2637664T3 (da) | 2010-10-15 | 2011-10-14 | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20120269898A1 (da) |
| EP (2) | EP3106163A1 (da) |
| JP (2) | JP5806320B2 (da) |
| KR (2) | KR20130069855A (da) |
| CN (1) | CN103458690B (da) |
| AR (1) | AR083422A1 (da) |
| AU (2) | AU2011315891B2 (da) |
| BR (1) | BR112013008983A2 (da) |
| CA (1) | CA2814518C (da) |
| CY (1) | CY1119007T1 (da) |
| DK (1) | DK2637664T3 (da) |
| EA (2) | EA026074B1 (da) |
| ES (1) | ES2627944T3 (da) |
| HR (1) | HRP20170848T1 (da) |
| HU (1) | HUE033346T2 (da) |
| LT (1) | LT2637664T (da) |
| MX (1) | MX346730B (da) |
| NZ (2) | NZ610012A (da) |
| PL (1) | PL2637664T3 (da) |
| PT (1) | PT2637664T (da) |
| RS (1) | RS56135B1 (da) |
| SI (1) | SI2637664T1 (da) |
| TW (1) | TWI542580B (da) |
| WO (1) | WO2012051559A2 (da) |
| ZA (1) | ZA201302746B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE025355T2 (en) | 2006-12-12 | 2016-02-29 | Gilead Sciences Inc | Composition for treating pulmonary hypertension |
| RS56135B1 (sr) | 2010-10-15 | 2017-10-31 | Gilead Sciences | Kompozicije i metode za lečenje plućne hipertenzije |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2014174529A2 (en) * | 2013-04-23 | 2014-10-30 | Hetero Research Foundation | Polymorphs of avanafil |
| WO2015069839A1 (en) * | 2013-11-06 | 2015-05-14 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
| CN105581990A (zh) * | 2014-08-27 | 2016-05-18 | 人福医药集团股份公司 | 安立生坦片剂及其制备方法 |
| CA2982436C (en) * | 2015-03-13 | 2023-09-12 | Indiana University Research And Technology Corporation | Targeting cgmp-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods |
| SI3496739T1 (sl) * | 2016-07-15 | 2021-06-30 | Acceleron Pharma Inc. | Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije |
| CA3041679A1 (en) * | 2016-10-27 | 2018-05-03 | Lawrence S. ZISMAN | Combination therapy for treating pulmonary hypertension |
| US20200215065A1 (en) * | 2017-07-07 | 2020-07-09 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and method for treating pulmonary hypertension |
| AU2018397436A1 (en) * | 2017-12-26 | 2020-08-13 | Ftf Pharma Private Limited | Liquid oral formulations for PDE V inhibitors |
| CN109406688A (zh) * | 2018-09-28 | 2019-03-01 | 中国食品药品检定研究院 | 用于检测产品中违禁药品的标准样品 |
| JP2023504115A (ja) * | 2019-11-29 | 2023-02-01 | アクテリオン ファーマシューティカルズ リミテッド | 肺動脈性肺高血圧症の治療方法 |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
| KR102606504B1 (ko) * | 2020-04-10 | 2023-11-29 | 주식회사 대웅테라퓨틱스 | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 |
| CN112826944B (zh) * | 2021-01-29 | 2023-08-15 | 台州职业技术学院 | 一种安立生坦包合物及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| UA46166C2 (uk) | 1997-11-12 | 2002-05-15 | Баєр Акцієнгезельшафт | 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| WO2006007213A1 (en) | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| CN101072564A (zh) * | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
| US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| BRPI0710658A2 (pt) | 2006-04-21 | 2011-08-16 | Pfizer Prod Inc | compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos |
| CA2669535A1 (en) * | 2006-12-12 | 2008-06-19 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorders |
| HUE025355T2 (en) * | 2006-12-12 | 2016-02-29 | Gilead Sciences Inc | Composition for treating pulmonary hypertension |
| MX2010001255A (es) | 2007-07-31 | 2010-12-06 | Gilead Colorado Inc | Metabolitos y derivados de ambrisentan. |
| WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| RS56135B1 (sr) | 2010-10-15 | 2017-10-31 | Gilead Sciences | Kompozicije i metode za lečenje plućne hipertenzije |
-
2011
- 2011-10-14 RS RS20170640A patent/RS56135B1/sr unknown
- 2011-10-14 EP EP16180914.0A patent/EP3106163A1/en not_active Withdrawn
- 2011-10-14 HU HUE11833507A patent/HUE033346T2/en unknown
- 2011-10-14 EA EA201390428A patent/EA026074B1/ru active IP Right Revival
- 2011-10-14 LT LTEP11833507.4T patent/LT2637664T/lt unknown
- 2011-10-14 ES ES11833507.4T patent/ES2627944T3/es active Active
- 2011-10-14 US US13/274,013 patent/US20120269898A1/en not_active Abandoned
- 2011-10-14 JP JP2013534043A patent/JP5806320B2/ja not_active Expired - Fee Related
- 2011-10-14 WO PCT/US2011/056404 patent/WO2012051559A2/en active Application Filing
- 2011-10-14 DK DK11833507.4T patent/DK2637664T3/da active
- 2011-10-14 BR BR112013008983A patent/BR112013008983A2/pt not_active IP Right Cessation
- 2011-10-14 PL PL11833507T patent/PL2637664T3/pl unknown
- 2011-10-14 MX MX2013004190A patent/MX346730B/es active IP Right Grant
- 2011-10-14 NZ NZ610012A patent/NZ610012A/en active IP Right Revival
- 2011-10-14 PT PT118335074T patent/PT2637664T/pt unknown
- 2011-10-14 TW TW100137481A patent/TWI542580B/zh not_active IP Right Cessation
- 2011-10-14 CN CN201180060879.3A patent/CN103458690B/zh not_active Expired - Fee Related
- 2011-10-14 CA CA2814518A patent/CA2814518C/en not_active Expired - Fee Related
- 2011-10-14 KR KR1020137012382A patent/KR20130069855A/ko active Search and Examination
- 2011-10-14 SI SI201131190A patent/SI2637664T1/sl unknown
- 2011-10-14 AU AU2011315891A patent/AU2011315891B2/en active Active
- 2011-10-14 KR KR20147032816A patent/KR20150002876A/ko not_active Application Discontinuation
- 2011-10-14 EA EA201691759A patent/EA201691759A1/ru unknown
- 2011-10-14 EP EP11833507.4A patent/EP2637664B1/en not_active Revoked
- 2011-10-14 NZ NZ707213A patent/NZ707213A/en active IP Right Revival
- 2011-10-17 AR ARP110103833A patent/AR083422A1/es unknown
-
2013
- 2013-04-17 ZA ZA2013/02746A patent/ZA201302746B/en unknown
- 2013-11-13 US US14/079,548 patent/US9549926B2/en active Active
-
2015
- 2015-06-10 JP JP2015117196A patent/JP2015178528A/ja not_active Withdrawn
-
2016
- 2016-07-04 AU AU2016204638A patent/AU2016204638B2/en not_active Ceased
- 2016-08-09 US US15/232,570 patent/US20160346280A1/en not_active Abandoned
-
2017
- 2017-06-05 HR HRP20170848TT patent/HRP20170848T1/hr unknown
- 2017-06-22 CY CY20171100660T patent/CY1119007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2637664T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
| KR101607081B1 (ko) | 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약 | |
| US20090048173A1 (en) | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | |
| US20230149393A1 (en) | Inhibitors of trpc6 for treating respiratory conditions | |
| CA2973114C (en) | Combination therapy for pulmonary hypertension | |
| US20120004188A1 (en) | Use of ranolazine for treating pulmonary hypertension | |
| US20150125546A1 (en) | Combination therapy for treating pulmonary hypertension | |
| AU2005205914A1 (en) | Combination of organic compounds | |
| US7888341B2 (en) | Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer | |
| RU2780758C2 (ru) | Комбинированная терапия легочной гипертензии | |
| US20220265617A1 (en) | Bet inhibitors as a treatment for myelofibrosis | |
| MXPA00009614A (en) | Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator |